

SECTION-1: Identification of the substance / mixture and the company / undertaking

Catalogue Number	CS-P-01005
Product Name	Fosamprenavir
CAS No.	226700-79-4
Category	API
Synonyms	Amprenavir phosphate
Brand	Clearsynth Labs Ltd.
Identified uses	Laboratory Chemicals
Uses advised against	Not available
Company	Clearsynth Labs Ltd. Mumbai, India
Emergency Phone #	+91-22-245045900
REACH No.	Not available

SECTION 2: Hazards identification

Disclaimer: This is sample MSDS. Please email sales@clearsynth.com for more details.

2.1 Classification of the substance or mixture-Regulation (EC) No 1272/2008:

Not available

2.2 Label Elements

Signal Word: Not available

Not available

Hazard Statement(s)

Code	Statement
Not available	Not available

Precautionary Statement(s)

Code	Statement
Not available	Not available

SECTION 3: Composition / information on ingredients

3.1 Substance

Component : Fosamprenavir
CAS Number : 226700-79-4
Molecular Formula : C₂₅H₃₆N₃O₉PS
Molecular Weight : 585.61
Parent Chemical : Fosamprenavir
Synonyms : Amprenavir phosphate
Concentration : Not available

SECTION 4: First aid measures

SECTION 4: First-aid measures

4.1 Description of first aid measures

- General advice: Seek medical attention if symptoms occur or persist. Show this SDS to the physician.
- Inhalation: Move person to fresh air. If breathing is difficult, seek medical attention.
- Skin contact: Wash with soap and water. Remove contaminated clothing and wash before reuse. Seek medical attention if irritation develops.
- Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing. Seek medical attention if irritation persists.
- Ingestion: Rinse mouth. Do not induce vomiting unless directed by medical personnel. Seek medical attention.

4.2 Most important symptoms and effects, both acute and delayed

- Not available.

4.3 Indication of any immediate medical attention and special treatment needed

- Treat symptomatically. No data available.

SECTION 5: Firefighting measures

SECTION 5: Fire-fighting measures

5.1 Extinguishing media

- Suitable extinguishing media: Water spray, alcohol-resistant foam, dry chemical, carbon dioxide (CO₂).
- Unsuitable extinguishing media: Not available.

5.2 Special hazards arising from the substance or mixture

- Specific hazards: Not available.
- Hazardous combustion products: Not available.

5.3 Advice for firefighters

- Wear self-contained breathing apparatus (SCBA) and full protective gear.
- Use water spray to cool unopened containers exposed to fire.
- Avoid inhalation of combustion products.

SECTION 6: Accidental release measures

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

- Avoid breathing dust.

- Avoid contact with skin and eyes.
- Use appropriate personal protective equipment (see Section 8).
- Ensure adequate ventilation.

6.2 Environmental precautions

- Prevent further leakage or spillage if safe to do so.
- Avoid release to the environment. Do not allow to enter drains/surface waters/groundwater.

6.3 Methods and material for containment and cleaning up

- Avoid generating dust.
- Collect spillage using methods that minimize dust generation (e.g., damp wipe, HEPA-filtered vacuum).
- Place in a suitable, closed container for disposal.

6.4 Reference to other sections

- See Section 8 for exposure controls/personal protection and Section 13 for disposal considerations.

SECTION-7: Handling and storage

SECTION 7: Handling and storage

7.1 Precautions for safe handling

- Handle in accordance with good industrial hygiene and safety practice.
- Avoid formation of dust and aerosols.
- Avoid contact with skin, eyes, and clothing.
- Do not breathe dust.
- Use with adequate ventilation; local exhaust recommended where dust may be generated.
- Wash hands thoroughly after handling.

7.2 Conditions for safe storage, including any incompatibilities

- Store in a tightly closed container.
- Store in a cool, dry, well-ventilated place.
- Protect from moisture.
- Incompatible materials: Not available.

7.3 Specific end use(s)

- API / laboratory and research use. Specific uses not available.

SECTION 8: Exposure controls / personal protection

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

- Occupational exposure limits: Not available.
- Biological limit values: Not available.

8.2 Exposure controls

- Appropriate engineering controls: Provide adequate ventilation. Use local exhaust ventilation where dust may be generated.
- Personal protective equipment (PPE):
 - Eye/face protection: Safety glasses with side shields or chemical goggles.
 - Skin protection: Protective gloves. Wear protective clothing as appropriate.

- Respiratory protection: If ventilation is inadequate or dust is generated, use a suitable particulate respirator.
- Hygiene measures: Wash hands after handling. Do not eat, drink, or smoke when using this product.

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Test	Result
Appearance	No data available
IR spectrum	No data available
pH	No data available
Solubility	No data available

Property	Value
a) Physical State	No data available
b) Color	No data available
c) Odor	No data available
d) pH	No data available
e) Vapour Pressure	No data available
f) Viscosity	No data available
g) Initial Boiling Point and boiling range	No data available
h) Melting Point / Freezing Point	No data available
i) Auto Ignition Temperature	No data available
j) Flash Point	No data available
k) Explosion Limit, Lower	No data available
l) Explosion Limit, Upper	No data available
m) Decomposition Temperature	No data available
n) Loss on Drying	No data available
o) Relative Density	No data available
p) Solubility (in DMSO)	No data available
q) Oxidizing Properties	No data available

SECTION 10: Stability and reactivity

SECTION 10: Stability and reactivity

10.1 Reactivity

- Not available.

10.2 Chemical stability

- Stable under recommended storage conditions.

10.3 Possibility of hazardous reactions

- Not available.

10.4 Conditions to avoid

- Avoid dust formation. Avoid exposure to moisture. Other conditions: Not available.

10.5 Incompatible materials

- Not available.

10.6 Hazardous decomposition products

- Not available.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

- Acute toxicity: /LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ The effects of fosamprenavir on fertility and general reproductive performance were evaluated in male and female rats administered a dose 3 to 4 times higher than the maximum recommended human dose (MRHD). Fosamprenavir did not impair mating or fertility of male or female rats and did not affect the development and maturation of sperm from treated rats.

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Embryo/fetal development studies were conducted in rats (dosed from day 6 to day 17 of gestation) and rabbits (dosed from day 7 to day 20 of gestation).

Administration of fosamprenavir to pregnant rats and rabbits produced no major effects on embryo-fetal development; however, the incidence of abortion was increased in rabbits that were administered fosamprenavir.

Systemic exposures (AUC 0-24 hr) to amprenavir at these dosages were 0.8 (rabbits) to 2 (rats) times the exposures in humans following administration of the maximum recommended human dose (MRHD) of fosamprenavir alone or 0.3 (rabbits) to 0.7 (rats) times the exposures in humans following administration of the MRHD of fosamprenavir in combination with ritonavir. In contrast, administration of amprenavir was associated with abortions and an increased incidence of minor skeletal variations resulting from deficient ossification of the femur, humerus, and trochlea, in pregnant rabbits at the tested dose; approximately one twentieth the exposure seen at the recommended human dose.

- Skin corrosion/irritation: No data available.

- Serious eye damage/eye irritation: No data available.

- Respiratory or skin sensitization: No data available.

- Germ cell mutagenicity: /GENOTOXICITY/ Fosamprenavir was not mutagenic or genotoxic in a battery of in vitro and in vivo assays, including bacterial reverse mutation (Ames), mouse lymphoma, rat micronucleus and chromosome aberrations in human lymphocytes.

- Carcinogenicity: /LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Amprenavir was evaluated for carcinogenic potential by oral gavage administration to mice and rats for up to 104 weeks. Results showed an increase in the incidence of benign hepatocellular adenomas and an increase in the combined incidence of hepatocellular adenomas plus carcinoma in males of both species at the highest doses tested. Female mice and

rats were not affected. These observations were made at systemic exposures equivalent to approximately 2 times (mice) and 4 times (rats) the human exposure (based on AUC 0-24 hr measurement) at the recommended dose...

- Reproductive toxicity: /LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ The effects of fosamprenavir on fertility and general reproductive performance were evaluated in male and female rats administered a dose 3 to 4 times higher than the maximum recommended human dose (MRHD). Fosamprenavir did not impair mating or fertility of male or female rats and did not affect the development and maturation of sperm from treated rats. /LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Embryo/fetal development studies were conducted in rats (dosed from day 6 to day 17 of gestation) and rabbits (dosed from day 7 to day 20 of gestation). Administration of fosamprenavir to pregnant rats and rabbits produced no major effects on embryo-fetal development; however, the incidence of abortion was increased in rabbits that were administered fosamprenavir. Systemic exposures (AUC 0-24 hr) to amprenavir at these dosages were 0.8 (rabbits) to 2 (rats) times the exposures in humans following administration of the maximum recommended human dose (MRHD) of fosamprenavir alone or 0.3 (rabbits) to 0.7 (rats) times the exposures in humans following administration of the MRHD of fosamprenavir in combination with ritonavir. In contrast, administration of amprenavir was associated with abortions and an increased incidence of minor skeletal variations resulting from deficient ossification of the femur, humerus, and trochlea, in pregnant rabbits at the tested dose; approximately one twentieth the exposure seen at the recommended human dose.
- STOT-single exposure: No data available.
- STOT-repeated exposure: /LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Amprenavir was evaluated for carcinogenic potential by oral gavage administration to mice and rats for up to 104 weeks. Results showed an increase in the incidence of benign hepatocellular adenomas and an increase in the combined incidence of hepatocellular adenomas plus carcinoma in males of both species at the highest doses tested. Female mice and rats were not affected. These observations were made at systemic exposures equivalent to approximately 2 times (mice) and 4 times (rats) the human exposure (based on AUC 0-24 hr measurement) at the recommended dose...
- Aspiration hazard: No data available.

Likely routes of exposure

- No data available.

Symptoms related to the physical, chemical and toxicological characteristics

- /SIGNS AND SYMPTOMS/ ... Severe or life-threatening skin reactions, including Stevens-Johnson syndrome, were reported in less than 1% of patients receiving fosamprenavir in clinical studies.

SECTION 12: Ecological information

SECTION 12: Ecological information

12.1 Toxicity

- Not available.

12.2 Persistence and degradability

- Not available.

12.3 Bioaccumulative potential

- Not available.

12.4 Mobility in soil

- Not available.

12.5 Results of PBT and vPvB assessment

- Not available.

12.6 Endocrine disrupting properties

- Not available.

12.7 Other adverse effects

- Not available.

SECTION 13: Disposal considerations

SECTION 13: Disposal considerations

13.1 Waste treatment methods

- Dispose of contents/container in accordance with local/regional/national/international regulations.
- Do not discharge to drains.
- Recommended disposal method: Not available.
- Contaminated packaging: Dispose of as unused product unless cleaned.

SECTION 14: Transport information

SECTION 14: Transport information

- UN number: Not available.
- UN proper shipping name: Not available.
- Transport hazard class(es): Not available.
- Packing group: Not available.
- Environmental hazards: Not available.
- Special precautions for user: Not available.
- Transport in bulk according to IMO instruments: Not available.

SECTION 15: Regulatory information

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

- Regulatory listings/classifications: Not available.

15.2 Chemical safety assessment

- Not available.

SECTION 16: Other information

SECTION 16: Other information

- Product name: Fosamprenavir
- CAS No.: 226700-79-4
- Catalog No.: CS-P-01005
- Synonyms: Amprenavir phosphate
- Supplier: Clearsynth Labs Ltd., Mumbai, India
- Emergency phone: +91-22-245045900

Disclaimer

- The information provided is believed to be accurate based on available data, but no warranty is expressed or implied. Users are responsible for determining suitability for their particular application and for compliance with applicable laws and regulations.

Revision information

- Revision date: Not available.
- Version: Not available.

DISCLAIMER

This MSDS is system-generated. Please verify and confirm all data, statements, and values with the Support Team before use or distribution.